Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 October 2022 | Story Dr Cinde Greyling | Photo Iflair Photography
UFS Business school
The UFS Business School.

The University of the Free State Business School (UFSBS) was established in the late 1990s and is fully accredited by the Council on Higher Education (CHE) and the Central and East European Management  Development Association (CEEMAN). Since its inception, the school has operated as a boutique business school focusing on personal attention to adult learners.

Late 2021, the UFSBS appointed a new Director, Dr Udesh Pillay. In conjunction with the change in leadership, the UFSBS is embarking on a new strategic journey, while maintaining the focus on its core business – in other words, its official academic offerings. The strategic journey of the UFSBS has been underway for the past year, and significant time has been allocated to the recurriculation of programme offerings; decolonisation of the academic agenda; and orientating the UFSBS so that it makes a larger practical contribution to the SME sector locally and nationally, especially in relation to business continuity and resilience in the wake of unforeseen externalities.  These developments will ensure that the UFSBS remains a premier academic institution and contributes to the success of South Africa and its people. It also ensures that the twin principles of academic excellence and social justice become mutually reinforcing.

The UFSBS’s strategic direction for the next five years aligns neatly with the Vision 130. By 2034 – when the university commemorates its 130th anniversary – the UFS wants to be recognised and acknowledged by peers and society as a top-tier university in South Africa. Similarly, the UFSBS has aspirations to become a top-ten business school in SA over the next five years.

Given the history of South Africa, it is of utmost importance to empower people to add value, particularly in the field of business and management leadership. The UFSBS will contribute to building an ecosystem of entrepreneurialism, with the more traditional academic programmes based upon the conventional practices of teaching and learning, research, and mentorship to be supplemented by ‘opportunity-driven initiatives’, such as executive education, consulting support, coaching, incubation services, and the commercialisation of intellectual property.

Globally, the Fourth Industrial Revolution (4IR) has catalysed processes of digital transformation in business, to which the UFSBS will align to ensure that students are equipped with the relevant knowledge and skills in a fast-changing, technology-enabled world. With the support of the Centre for Business Dynamics (CBD) housed in the UFSBS; the establishment of the Small Business Academy (SBA) in early 2024 in the UFSBS; the soon-to-be-established High-Growth Business Incubator (in collaboration with the NAS faculty); and with the process of strengthening relationships with the Paradys Experimental Farm gaining traction, a differentiated medium has been created to nurture responsible,  ethical, and socially conscious business leaders. The foundation then – to create the next generation of business leaders and entrepreneurs to become agents of change and value co-creators for business and society – will thus have begun.

The UFSBS will align to ensure that students are equipped with relevant knowledge and skills in a fast-changing, technology-enabled world. – Dr Udesh Pillay.
The slogan, ‘BE WORTH MORE’, embodies what the UFSBS strives for, and is consistent with new developments in global discourses, which are rethinking and transforming many of the traditional dogmas that have informed the mandates of business schools. 

As a critical bridge between academia and business, the UFSBS is uniquely poised to reimagine a better and intelligent future that is data-informed, collaborative, innovative, and inclusive.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept